Skip to main content
Erschienen in: Endocrine 2/2013

01.10.2013 | Original Article

Vitamin D status and 5-year changes in urine albumin creatinine ratio and parathyroid hormone in a general population

verfasst von: Tea Skaaby, Lise Lotte Nystrup Husemoen, Charlotta Pisinger, Torben Jørgensen, Betina Heinsbæk Thuesen, Knud Rasmussen, Mogens Fenger, Peter Rossing, Allan Linneberg

Erschienen in: Endocrine | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Vitamin D is associated with cardiovascular disease and renal function but the mechanisms are as yet unexplained. Microalbuminuria is associated with a higher risk of kidney function loss, cardiovascular disease, and mortality. Parathyroid hormone is a predictor of cardiovascular mortality and negatively correlated with glomerular filtration rate. We investigated the association between vitamin D status and 5-year changes in urine albumin creatinine ratio (UACR) and parathyroid hormone (PTH). A random sample of 6,784 individuals aged 30−60 years from a general population participated in the Inter99 study in 1999–2001. Vitamin D (serum-25-hydroxyvitamin D) was measured at baseline by high-performance liquid chromatography. UACR and PTH were measured at baseline and follow-up. Increased UACR was defined as UACR >4.0 mg/g reflecting the upper quartile at baseline. We included 4,330 individuals who participated at 5-year follow-up. In multivariable linear regression analysis, a 10-nmol/l higher baseline level of vitamin D was associated with a 5-year decrease in UACR by 0.92 % (95 % confidence interval, CI 0.13, 1.71). In multivariable logistic regression analysis, the odds ratio of developing increased UACR during follow-up was 0.96 (95 % CI 0.92, 0.98) per 10 nmol/l higher baseline vitamin D level. We found a significant inverse cross-sectional (p < 0.0001) but no prospective association (p = 0.6) between baseline vitamin D status and parathyroid hormone. We found low vitamin D status to be a predictor of long-term development of increased UACR. It remains to be proven whether vitamin D deficiency is a causal and reversible factor in the development of albuminuria.
Literatur
1.
Zurück zum Zitat L.G. Danescu, S. Levy, J. Levy, Vitamin D and diabetes mellitus. Endocrine 35, 11–17 (2009)PubMedCrossRef L.G. Danescu, S. Levy, J. Levy, Vitamin D and diabetes mellitus. Endocrine 35, 11–17 (2009)PubMedCrossRef
3.
Zurück zum Zitat P. Greenland, J.S. Alpert, G.A. Beller, E.J. Benjamin, M.J. Budoff et al., 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 56, e50–e103 (2010)PubMedCrossRef P. Greenland, J.S. Alpert, G.A. Beller, E.J. Benjamin, M.J. Budoff et al., 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 56, e50–e103 (2010)PubMedCrossRef
4.
Zurück zum Zitat H.J. Lambers Heerspink, J.W. Brinkman, S.J. Bakker, R.T. Gansevoort, de ZD, Update on microalbuminuria as a biomarker in renal and cardiovascular disease. Curr. Opin. Nephrol. Hypertens. 15, 631–636 (2006)PubMedCrossRef H.J. Lambers Heerspink, J.W. Brinkman, S.J. Bakker, R.T. Gansevoort, de ZD, Update on microalbuminuria as a biomarker in renal and cardiovascular disease. Curr. Opin. Nephrol. Hypertens. 15, 631–636 (2006)PubMedCrossRef
5.
Zurück zum Zitat C.S. Sheng, B.C. Hu, W.X. Fan, J. Zou, Y. Li et al., Microalbuminuria in relation to the metabolic syndrome and its components in a Chinese population. Diabetol. Metab. Syndr. 3, 6 (2011)PubMedCrossRef C.S. Sheng, B.C. Hu, W.X. Fan, J. Zou, Y. Li et al., Microalbuminuria in relation to the metabolic syndrome and its components in a Chinese population. Diabetol. Metab. Syndr. 3, 6 (2011)PubMedCrossRef
6.
Zurück zum Zitat de ZD, G. Remuzzi, H.H. Parving, W.F. Keane, Z. Zhang et al., Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110, 921–927 (2004)CrossRef de ZD, G. Remuzzi, H.H. Parving, W.F. Keane, Z. Zhang et al., Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110, 921–927 (2004)CrossRef
7.
Zurück zum Zitat H. Ibsen, M.H. Olsen, K. Wachtell, K. Borch-Johnsen, L.H. Lindholm et al., Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients with left ventricular hypertrophy and diabetes. J. Nephrol. 21, 566–569 (2008)PubMed H. Ibsen, M.H. Olsen, K. Wachtell, K. Borch-Johnsen, L.H. Lindholm et al., Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients with left ventricular hypertrophy and diabetes. J. Nephrol. 21, 566–569 (2008)PubMed
8.
Zurück zum Zitat I.H. de Boer, G.N. Ioannou, B. Kestenbaum, J.D. Brunzell, N.S. Weiss, 25-Hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). Am. J. Kidney Dis. 50, 69–77 (2007)PubMedCrossRef I.H. de Boer, G.N. Ioannou, B. Kestenbaum, J.D. Brunzell, N.S. Weiss, 25-Hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). Am. J. Kidney Dis. 50, 69–77 (2007)PubMedCrossRef
9.
Zurück zum Zitat Z.D. de, R. Agarwal, M. Amdahl, P. Audhya, D. Coyne et al., Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 376, 1543–1551 (2010)CrossRef Z.D. de, R. Agarwal, M. Amdahl, P. Audhya, D. Coyne et al., Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 376, 1543–1551 (2010)CrossRef
10.
Zurück zum Zitat L. Steingrimsdottir, O. Gunnarsson, O.S. Indridason, L. Franzson, G. Sigurdsson, Relationship between serum parathyroid hormone levels, vitamin D sufficiency, and calcium intake. JAMA 294, 2336–2341 (2005)PubMedCrossRef L. Steingrimsdottir, O. Gunnarsson, O.S. Indridason, L. Franzson, G. Sigurdsson, Relationship between serum parathyroid hormone levels, vitamin D sufficiency, and calcium intake. JAMA 294, 2336–2341 (2005)PubMedCrossRef
11.
Zurück zum Zitat E. Hagstrom, P. Hellman, T.E. Larsson, E. Ingelsson, L. Berglund et al., Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation 119, 2765–2771 (2009)PubMedCrossRef E. Hagstrom, P. Hellman, T.E. Larsson, E. Ingelsson, L. Berglund et al., Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation 119, 2765–2771 (2009)PubMedCrossRef
12.
Zurück zum Zitat H. Reichel, B. Deibert, H. Schmidt-Gayk, E. Ritz, Calcium metabolism in early chronic renal failure: implications for the pathogenesis of hyperparathyroidism. Nephrol. Dial. Transpl. 6, 162–169 (1991)CrossRef H. Reichel, B. Deibert, H. Schmidt-Gayk, E. Ritz, Calcium metabolism in early chronic renal failure: implications for the pathogenesis of hyperparathyroidism. Nephrol. Dial. Transpl. 6, 162–169 (1991)CrossRef
13.
Zurück zum Zitat S. Ozmen, R. Danis, D. Akin, T. Cil, O. Yazanel, Parathyroid hormone as a marker for the differential diagnosis of acute and chronic renal failure. Ren. Fail. 29, 509–512 (2007)PubMedCrossRef S. Ozmen, R. Danis, D. Akin, T. Cil, O. Yazanel, Parathyroid hormone as a marker for the differential diagnosis of acute and chronic renal failure. Ren. Fail. 29, 509–512 (2007)PubMedCrossRef
14.
Zurück zum Zitat K/DOQI, Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am. J. Kidney Dis. 42, S1–S201 (2003) K/DOQI, Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am. J. Kidney Dis. 42, S1–S201 (2003)
15.
Zurück zum Zitat C.M. O’Seaghdha, S.J. Hwang, R. Holden, S.L. Booth, C.S. Fox, Phylloquinone and vitamin D Status: associations with incident chronic kidney disease in the framingham offspring cohort. Am. J. Nephrol. 36, 68–77 (2012)PubMedCrossRef C.M. O’Seaghdha, S.J. Hwang, R. Holden, S.L. Booth, C.S. Fox, Phylloquinone and vitamin D Status: associations with incident chronic kidney disease in the framingham offspring cohort. Am. J. Nephrol. 36, 68–77 (2012)PubMedCrossRef
16.
Zurück zum Zitat T. Jorgensen, K. Borch-Johnsen, T.F. Thomsen, H. Ibsen, C. Glumer et al., A randomized non-pharmacological intervention study for prevention of ischaemic heart disease: baseline results Inter99. Eur. J. Cardiovasc. Prev. Rehabil. 10, 377–386 (2003)PubMedCrossRef T. Jorgensen, K. Borch-Johnsen, T.F. Thomsen, H. Ibsen, C. Glumer et al., A randomized non-pharmacological intervention study for prevention of ischaemic heart disease: baseline results Inter99. Eur. J. Cardiovasc. Prev. Rehabil. 10, 377–386 (2003)PubMedCrossRef
17.
Zurück zum Zitat U. Toft, L. Kristoffersen, S. Ladelund, A. Bysted, J. Jakobsen et al., Relative validity of a food frequency questionnaire used in the Inter99 study. Eur. J. Clin. Nutr. 62, 1038–1046 (2008)PubMedCrossRef U. Toft, L. Kristoffersen, S. Ladelund, A. Bysted, J. Jakobsen et al., Relative validity of a food frequency questionnaire used in the Inter99 study. Eur. J. Clin. Nutr. 62, 1038–1046 (2008)PubMedCrossRef
18.
Zurück zum Zitat T. Skaaby, L.L. Husemoen, C. Pisinger, T. Jorgensen, B.H. Thuesen et al., Vitamin D status and incident cardiovascular disease and all-cause mortality: a general population study. Endocrine 7, e52423 (2012) T. Skaaby, L.L. Husemoen, C. Pisinger, T. Jorgensen, B.H. Thuesen et al., Vitamin D status and incident cardiovascular disease and all-cause mortality: a general population study. Endocrine 7, e52423 (2012)
19.
Zurück zum Zitat B. Thuesen, L. Husemoen, M. Fenger, J. Jakobsen, P. Schwarz et al., Determinants of vitamin D status in a general population of Danish adults. Bone 50, 605–610 (2012)PubMedCrossRef B. Thuesen, L. Husemoen, M. Fenger, J. Jakobsen, P. Schwarz et al., Determinants of vitamin D status in a general population of Danish adults. Bone 50, 605–610 (2012)PubMedCrossRef
20.
Zurück zum Zitat J. Jakobsen, A. Bysted, R. Andersen, T. Bennett, C. Brot et al., Vitamin D status assessed by a validated HPLC method: within and between variation in subjects supplemented with vitamin D3. Scand. J. Clin. Lab. Invest. 69, 190–197 (2009)PubMedCrossRef J. Jakobsen, A. Bysted, R. Andersen, T. Bennett, C. Brot et al., Vitamin D status assessed by a validated HPLC method: within and between variation in subjects supplemented with vitamin D3. Scand. J. Clin. Lab. Invest. 69, 190–197 (2009)PubMedCrossRef
21.
Zurück zum Zitat Obesity: Preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 894(i–xii), 1–253 (2000) Obesity: Preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 894(i–xii), 1–253 (2000)
22.
Zurück zum Zitat World Health Organization. Use of Glycated Haemoglobin in the Diagnosis of Diabetes Mellitus. Abbreviated Report of a WHO Consultation. (2011) World Health Organization. Use of Glycated Haemoglobin in the Diagnosis of Diabetes Mellitus. Abbreviated Report of a WHO Consultation. (2011)
23.
Zurück zum Zitat A.J. Vickers, D.G. Altman, Statistics notes: Analysing controlled trials with baseline and follow up measurements. BMJ 323, 1123–1124 (2001)PubMedCrossRef A.J. Vickers, D.G. Altman, Statistics notes: Analysing controlled trials with baseline and follow up measurements. BMJ 323, 1123–1124 (2001)PubMedCrossRef
24.
Zurück zum Zitat N.C. Bozkurt, E. Cakal, M. Sahin, E.C. Ozkaya, H. Firat et al., The relation of serum 25-hydroxyvitamin-D levels with severity of obstructive sleep apnea and glucose metabolism abnormalities. Endocrine 41, 518–525 (2012)PubMedCrossRef N.C. Bozkurt, E. Cakal, M. Sahin, E.C. Ozkaya, H. Firat et al., The relation of serum 25-hydroxyvitamin-D levels with severity of obstructive sleep apnea and glucose metabolism abnormalities. Endocrine 41, 518–525 (2012)PubMedCrossRef
25.
Zurück zum Zitat L.L. Husemoen, B.H. Thuesen, M. Fenger, T. Jorgensen, C. Glumer et al., Serum 25(OH)D and Type 2 diabetes association in a general population: a prospective study. Diabetes Care 35, 1695–1700 (2012)PubMedCrossRef L.L. Husemoen, B.H. Thuesen, M. Fenger, T. Jorgensen, C. Glumer et al., Serum 25(OH)D and Type 2 diabetes association in a general population: a prospective study. Diabetes Care 35, 1695–1700 (2012)PubMedCrossRef
26.
Zurück zum Zitat L.L. Husemoen, T. Skaaby, B.H. Thuesen, T. Jorgensen, R.V. Fenger et al., Serum 25(OH)D and incident type 2 diabetes: a cohort study. Eur. J. Clin. Nutr. 66(12), 1309–1314 (2012)PubMedCrossRef L.L. Husemoen, T. Skaaby, B.H. Thuesen, T. Jorgensen, R.V. Fenger et al., Serum 25(OH)D and incident type 2 diabetes: a cohort study. Eur. J. Clin. Nutr. 66(12), 1309–1314 (2012)PubMedCrossRef
27.
Zurück zum Zitat W.B. Grant, Effect of interval between serum draw and follow-up period on relative risk of cancer incidence with respect to 25-hydroxyvitamin D level: Implications for meta-analyses and setting vitamin D guidelines. Dermatoendocrinol. 3, 199–204 (2011)PubMed W.B. Grant, Effect of interval between serum draw and follow-up period on relative risk of cancer incidence with respect to 25-hydroxyvitamin D level: Implications for meta-analyses and setting vitamin D guidelines. Dermatoendocrinol. 3, 199–204 (2011)PubMed
28.
Zurück zum Zitat E.C. Witte, H.J. Lambers Heerspink, de ZD, S.J. Bakker, P.E. de Jong et al., First morning voids are more reliable than spot urine samples to assess microalbuminuria. J. Am. Soc. Nephrol. 20, 436–443 (2009)PubMedCrossRef E.C. Witte, H.J. Lambers Heerspink, de ZD, S.J. Bakker, P.E. de Jong et al., First morning voids are more reliable than spot urine samples to assess microalbuminuria. J. Am. Soc. Nephrol. 20, 436–443 (2009)PubMedCrossRef
29.
Zurück zum Zitat T. Babazono, C. Takahashi, Y. Iwamoto, Definition of microalbuminuria in first-morning and random spot urine in diabetic patients. Diabetes Care 27, 1838–1839 (2004)PubMedCrossRef T. Babazono, C. Takahashi, Y. Iwamoto, Definition of microalbuminuria in first-morning and random spot urine in diabetic patients. Diabetes Care 27, 1838–1839 (2004)PubMedCrossRef
30.
Zurück zum Zitat H. Martin, Laboratory measurement of urine albumin and urine total protein in screening for proteinuria in chronic kidney disease. Clin. Biochem. Rev. 32, 97–102 (2011)PubMed H. Martin, Laboratory measurement of urine albumin and urine total protein in screening for proteinuria in chronic kidney disease. Clin. Biochem. Rev. 32, 97–102 (2011)PubMed
31.
Zurück zum Zitat R. Jorde, M. Sneve, M. Hutchinson, N. Emaus, Y. Figenschau et al., Tracking of serum 25-hydroxyvitamin D levels during 14 years in a population-based study and during 12 months in an intervention study. Am. J. Epidemiol. 171, 903–908 (2010)PubMedCrossRef R. Jorde, M. Sneve, M. Hutchinson, N. Emaus, Y. Figenschau et al., Tracking of serum 25-hydroxyvitamin D levels during 14 years in a population-based study and during 12 months in an intervention study. Am. J. Epidemiol. 171, 903–908 (2010)PubMedCrossRef
32.
Zurück zum Zitat M.C. Ocke, J. Schrijver, Obermann-de Boer GL, Bloemberg BP, Haenen GR, et al. Stability of blood (pro)vitamins during four years of storage at −20 °C: consequences for epidemiologic research. J. Clin. Epidemiol. 48, 1077–1085 (1995)PubMedCrossRef M.C. Ocke, J. Schrijver, Obermann-de Boer GL, Bloemberg BP, Haenen GR, et al. Stability of blood (pro)vitamins during four years of storage at −20 °C: consequences for epidemiologic research. J. Clin. Epidemiol. 48, 1077–1085 (1995)PubMedCrossRef
33.
Zurück zum Zitat J.P. Wielders, F.A. Wijnberg, Preanalytical stability of 25(OH)-vitamin D3 in human blood or serum at room temperature: solid as a rock. Clin. Chem. 55, 1584–1585 (2009)PubMedCrossRef J.P. Wielders, F.A. Wijnberg, Preanalytical stability of 25(OH)-vitamin D3 in human blood or serum at room temperature: solid as a rock. Clin. Chem. 55, 1584–1585 (2009)PubMedCrossRef
34.
Zurück zum Zitat G.D. Carter, C.R. Carter, E. Gunter, J. Jones, G. Jones et al., Measurement of Vitamin D metabolites: an international perspective on methodology and clinical interpretation. J. Steroid Biochem. Mol. Biol. 89–90, 467–471 (2004)PubMedCrossRef G.D. Carter, C.R. Carter, E. Gunter, J. Jones, G. Jones et al., Measurement of Vitamin D metabolites: an international perspective on methodology and clinical interpretation. J. Steroid Biochem. Mol. Biol. 89–90, 467–471 (2004)PubMedCrossRef
35.
Zurück zum Zitat G.D. Carter, 25-Hydroxyvitamin D assays: the quest for accuracy. Clin. Chem. 55, 1300–1302 (2009)PubMedCrossRef G.D. Carter, 25-Hydroxyvitamin D assays: the quest for accuracy. Clin. Chem. 55, 1300–1302 (2009)PubMedCrossRef
36.
Zurück zum Zitat P. Glendenning, M. Taranto, J.M. Noble, A.A. Musk, C. Hammond et al., Current assays overestimate 25-hydroxyvitamin D3 and underestimate 25-hydroxyvitamin D2 compared with HPLC: need for assay-specific decision limits and metabolite-specific assays. Ann. Clin. Biochem. 43, 23–30 (2006)PubMedCrossRef P. Glendenning, M. Taranto, J.M. Noble, A.A. Musk, C. Hammond et al., Current assays overestimate 25-hydroxyvitamin D3 and underestimate 25-hydroxyvitamin D2 compared with HPLC: need for assay-specific decision limits and metabolite-specific assays. Ann. Clin. Biochem. 43, 23–30 (2006)PubMedCrossRef
37.
Zurück zum Zitat G. Snellman, H. Melhus, R. Gedeborg, L. Byberg, L. Berglund et al., Determining vitamin D status: a comparison between commercially available assays. PLoS ONE 5, e11555 (2010)PubMedCrossRef G. Snellman, H. Melhus, R. Gedeborg, L. Byberg, L. Berglund et al., Determining vitamin D status: a comparison between commercially available assays. PLoS ONE 5, e11555 (2010)PubMedCrossRef
Metadaten
Titel
Vitamin D status and 5-year changes in urine albumin creatinine ratio and parathyroid hormone in a general population
verfasst von
Tea Skaaby
Lise Lotte Nystrup Husemoen
Charlotta Pisinger
Torben Jørgensen
Betina Heinsbæk Thuesen
Knud Rasmussen
Mogens Fenger
Peter Rossing
Allan Linneberg
Publikationsdatum
01.10.2013
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 2/2013
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-013-9887-0

Weitere Artikel der Ausgabe 2/2013

Endocrine 2/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.